Results 11 to 20 of about 188,451 (293)
Haematologica, 2013 The BCR-ABL T315I mutation confers resistance to currently licensed tyrosine kinase inhibitors in chronic myelogenous leukemia. However, the impact of this mutation on survival in early stages of disease, in chronic phase, has never been detailed.
Franck E. Nicolini +24 more
doaj +2 more sources
BMC Complementary and Alternative Medicine, 2012 Background In this report, the isorhamnetin 3-o-robinobioside and its original extract, the ethyl acetate extract, from Nitraria retusa leaves, were evaluated for their ability to induce antioxidant and antigenotoxic effects in human chronic myelogenous ...
Boubaker Jihed +4 more
doaj +2 more sources
Nature Communications, 2021 Identifying novel drug targets to overcome resistance to tyrosine kinase inhibitors (TKIs) and eradicating leukemia stem/progenitor cells are required for the treatment of chronic myelogenous leukemia (CML).
Hu Lei +21 more
semanticscholar +1 more source
Acute appendicitis revealing a diagnosis of chronic myelogenous leukemia
Clinical Case Reports, 2021 Gastrointestinal manifestations of leukemias have been well recognized. Typically, acute leukemias cause typhlitis or appendicitis more commonly than chronic leukemias.
Rita Ahmad +6 more
doaj +1 more source
Juvenile Chronic Myelogenous Leukemia [PDF]
American Journal of Clinical Pathology, 1996 Juvenile chronic myelogenous leukemia (JCML) is an aggressive myeloproliferative disorder of childhood that differs both clinically and pathologically from adult type, Philadelphia chromosome positive chronic myelogenous leukemia, and from the other myeloproliferative disorders that are more common in adulthood.
J L, Hess +3 more
openaire +2 more sources
A study on the cytomorphologic structure of blood cells by vital staining II. Leukemic cells in the bone marrow [PDF]
, 1960 Leukemic cells were cytologically studied in the human bone marrow culture by the utilization of vital staining of Janus green B and neutral red. The minute cellular morphology of various types of leukemia was studied with special reference to their ...
Ota, Zensuke
core +1 more source
Epigenetic dysregulation in chronic myeloid leukaemia: A myriad of mechanisms and therapeutic options [PDF]
, 2018 The onset of global epigenetic changes in chromatin that drive tumor proliferation and heterogeneity is a hallmark of many forms cancer. Identifying the epigenetic mechanisms that govern these changes and developing therapeutic approaches to modulate ...
Koschmieder, Steffen, Vetrie, David
core +1 more source
The chronic myeloid leukemia stem cell: stemming the tide of persistence [PDF]
, 2017 Chronic myeloid leukaemia (CML) is caused by the acquisition of the tyrosine kinase BCR-ABL1 in a haemopoietic stem cell (HSC), transforming it into a leukaemic stem cell (LSC) that self-renews, proliferates and differentiates to give rise to a ...
Holyoake, Tessa L., Vetrie, David
core +1 more source
Dasatinib: ten years of clinical practice worldwide
Онкогематология, 2016 The article contains results of meta-analysis of experience in use of second-generation tyrosine kinase inhibitors – dasatinib. The results of clinical trials dasatinib therapy in chronic myelogenous leukemia imatinib-resistant or intolerant patients are
K. M. Abdulkadyrov +2 more
doaj +1 more source
Inhibition of interleukin-1 signaling enhances elimination of tyrosine kinase inhibitor treated CML stem cells [PDF]
, 2016 Treatment of chronic myelogenous leukemia (CML) with BCR-ABL tyrosine kinase inhibitors (TKI) fails to eliminate leukemia stem cells (LSC). Patients remain at risk for relapse, and additional approaches to deplete CML LSC are needed to enhance the ...
Agarwal, Puneet +9 more
core +1 more source